For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Nurix Therapeutics, Inc.

USPTO Granted Patents = 14

EPO Patents = 3

Trademarks = 5

Forward Citations = 26

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Arthur T Sands (11 out of 11 patents)

Dahlia Weiss (8 out of 8 patents)

Hunter Paul Shunatona (8 out of 25 patents)

4. Frederick Cohen (7 out of 27 patents)

5. Jennifa Gosling (7 out of 11 patents)

6. Neil F Bence (6 out of 6 patents)

7. Chenbo Wang (6 out of 6 patents)

8. Thomas Cummins (6 out of 6 patents)

9. Hiroko Tanaka (6 out of 6 patents)

10. Christoph Wolfgang Zapf (6 out of 22 patents)

11. Mario G Cardozo (6 out of 22 patents)

12. John Buell (2 out of 15 patents)

13. Joel McIntosh (2 out of 14 patents)

14. Daniel W Robbins (2 out of 2 patents)

15. Jeffrey Wu (2 out of 3 patents)

14 patents: Sort by Forward Citations

1. 12377106 - Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK (2025-08-05),

2. 12234230 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof (2025-02-25),

3. 12121540 - CBL inhibitors and compositions for use in adoptive cell therapy (2024-10-22),

4. 12091426 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof (2024-09-17),

5. 12049471 - Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof (2024-07-30),

6. 12016860 - Combination therapies with Cbl-b inhibitor compounds (2024-06-25),

7. 11951133 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof (2024-04-09),

8. 11866442 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2024-01-09),

9. 11820781 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2023-11-21),

10. 11739101 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof (2023-08-29),

11. 11530229 - Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof (2022-12-20),

12. 11479556 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2022-10-25),

13. 11464802 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof (2022-10-11),

14. 11401267 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof (2022-08-02),

Nurix Therapeutics is a biopharmaceutical company focused on developing novel therapies that target the ubiquitin proteasome system to treat cancer and other diseases. Their proprietary drug discovery platform enables the identification of small molecule modulators of E3 ligases, a key component of the ubiquitin proteasome system. Through strategic collaborations and internal research programs, Nurix is advancing a pipeline of potential therapeutics for a variety of indications.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#326 in San Francisco, CA

#5,157 in California

#21,642 in US

#40,929 in the World

San Francisco, CA, United States of America

Nurix Therapeutics, Inc.

Forward Citations = 26

28 inventors:

Arthur T Sands (11 out of 11 patents)

Dahlia Weiss (8 out of 8 patents)

Hunter Paul Shunatona (8 out of 25 patents)

4. Frederick Cohen (7 out of 27 patents)

5. Jennifa Gosling (7 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…